Branden Shaffer, OD
Optometrist · Indianapolis, INNPI 1568014330
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,917 and has fallen 55.8% since, to $1,290 in 2025. Among optometrist clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $46.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$2K
- AbbVie$2K
- Glaukos Corporation$2K
- Alcon$691
- Bausch & Lomb Americas Inc.$544
- Rxsight Inc$357
- plus $3K from 20 others
What the payments were for
- Food & beverage$9,445100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lensar, Inc. | 7 | $1,861 |
| AbbVie(2 entities) | 45 | $1,637 |
| Glaukos Corporation | 29 | $1,600 |
| Alcon | 24 | $691 |
| Bausch & Lomb Americas Inc. | 17 | $544 |
| Rxsight Inc | 13 | $357 |
| Dompe US, Inc. | 3 | $312 |
| Aerie Pharmaceuticals, Inc. | 4 | $257 |
| Thea Pharma Inc. | 4 | $253 |
| Novartis | 16 | $239 |
| Tarsus Pharmaceuticals, Inc. | 7 | $203 |
| Harrow Eye, LLC | 4 | $184 |
| Apellis Pharmaceuticals, Inc. | 2 | $137 |
| Johnson & Johnson Vision Care, Inc. | 1 | $127 |
| Sun Pharmaceutical Industries Inc. | 1 | $124 |
| Mallinckrodt Hospital Products Inc. | 1 | $123 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $123 |
| Astellas Pharma US Inc | 1 | $121 |
| Sight Sciences, Inc. | 5 | $105 |
| Kala Pharmaceuticals, Inc. | 1 | $98 |
| NEW World Medical,inc. | 5 | $96 |
| Ivantis, Inc | 2 | $86 |
| Oyster Point Pharma, Inc. | 4 | $71 |
| Coopervision Inc. | 1 | $61 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
| LKC Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$1,846
- DURYSTA$594
- iStent infinite Trabecular Micro-Bypass System Model iS3$507
- Rhopressa$235
- Rocklatan$235
- iDose$205
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$173
- iStent Infinite$139
- iDoseTR$139
- RADIUS$136
- Acuvue$127
- VEVYE$125
- LUMIGAN$125
- XEN GLAUCOMA TREATMENT SYSTEM$125
- Oxervate$124
- Syfovre$124
- VYZULTA$124
- CEQUA$124
- XELPROS$124
- BROMSITE$124
How this compares
$9,445 in reported general payments places this provider in the 95th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 37 | $54,003 |
| LumiganBimatoprost | 103 | $46,493 |
| RestasisCyclosporine | 19 | $26,806 |
| RocklatanNetarsudil Mesylat/Latanoprost | 35 | $18,045 |
| RhopressaNetarsudil Mesylate | 37 | $17,173 |
| CombiganBrimonidine Tartrate/Timolol | 38 | $15,300 |
| MieboPerfluorohexyloctane/Pf | 16 | $12,113 |
| VevyeCyclosporine | 15 | $10,937 |
| TyrvayaVarenicline Tartrate | 15 | $9,741 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $7,530 |
| Latanoprost | 477 | $5,129 |
| VyzultaLatanoprostene Bunod | 13 | $4,754 |
| Prednisolone Acetate | 121 | $3,864 |
| Alphagan PBrimonidine Tartrate | 11 | $3,355 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,637 | $91,953171 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $544 | $70,87066 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $257 | $35,21772 claims |
| Harrow Eye, LLCVevye | $184 | $10,93715 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $71 | $9,74115 claims |
| AlconSimbrinza | $691 | $7,53030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,318 optometrist providers in Indiana.
Other optometrist in Indianapolis
- Damon DierkerIndianapolis$707K
- Rhonda RobinsonIndianapolis$205K
- Brenda WahlIndianapolis$38K
- Peter KoernerIndianapolis$11K
- Jessica HultsIndianapolis$10K
- Scott AllisonIndianapolis$8K
- Alma NoreikaIndianapolis$7K
- Scott HastyIndianapolis$7K
- Diana FisherIndianapolis$7K
- Nathan MorrowIndianapolis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.